LU Yang
Principal Investigator
Lu Yang has been engaged in drug research and development for more than 30 years, and created the first technology platform of chemical drug crystal form in China. She is editor-in-chief of China's first academic monograph "Polymorphic Drugs". Lv has presided over the completion of the "Chinese Pharmacopoeia" guidelines for drug crystal form research and crystal form quality control, promoted the scientific and technological progress of polymorphic drugs, improved the quality and efficacy of China’s innovative and generic polymorphic drugs in accordance with international standards. She took the lead in developing national-level certified standard substances of metered chemical purity and crystal form drugs that meet international standards. She has obtained 212 national-level standard substances traceable to the international SI unit, and promoted the international mutual recognition of the standard of pharmaceutical substances in China. More than 120 domestic and foreign invention patent applications have been filed, and more than 60 patents have been authorized. As chief/associate editor, she has published 2 academic monographs, 9 participating works and more than 300 research papers.
1. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet , 2020, 395(10236): 1569-1578.
2. The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro. Biochemical Pharmacology , 2021, 183, 114302.
3. Control over Polymorph Formation of Polydatin in Binary Solvent System and Structural Characterization. Journal of Pharmaceutical and Biomedical Analysis, 2020, 190, 113260.
4. Versatile Salts as a Strategy to Modify the Biopharmaceutical Properties of Venlafaxine and a Potential Hy poglycemic Effect Study. Crystal Growth & Design , 2020, 20, 3131-3139.
5. Characterization of a New Solvatomorph of Drospirenone by Thermogravimetry-Mass Spectrometry Combined with Other Solid-State Analysis Methods. ACS Omega . 2020, 5(39): 25289-25296.
6. Anti-inflammatory Effects and Mechanisms of Rhein, an Anthraquinone Compound, and Its Applications in Treating Arthritis: A Review. Natural Products and Bioprospecting . 2020, 10(6): 445-452.
7. A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats. Pharmaceutics , 2020, 12(10): 906.
8. Structural and Computational Insights into Cocrystal Interactions: A Case on Cocrystals of Antipyrine and Aminophenazone. Crystal Growth & Design , 2019, 19(11): 6175-6183.
9. Salt screening and characterization of ciprofloxacin. Acta crystallographica section B , 2016, 72 (1): 20-28.
10. Study on four polymorphs of bifendate based on x-ray crystallography. Acta Pharmaceutica Sinica B , 2016, 6(3): 234-242.
1. Polymorphic Drugs 2009 (1st Edition). Lu, Y., and Du, G.H. Edited by Gao B. and Kuang L.J. People's Medical Publishing House , Pages 1-345. Print ISBN: 978-7-117-11571-1.
2. Polymorphic Drugs 2019 (2nd Edition). Lu, Y., and Du, G.H. Edited by Cheng Y. People's Medical Publishing House , Pages 1-430. Print ISBN: 978-7-117-28034-1.
3. Natural Small Molecule Drugs from Plants. Du, G.H., Fang L.H., Lu, Y., Chen N.H., Wang J.H., Qin X.M. Edited by Cao J.H. People's Medical Publishing House, Pages 1-332. Print ISBN: 978-7-117-24870-9.
4. Review of ancient and modern studies on Chinese herbal medicine toxicity. Du, G.H., Lu, Y. Edited by Kuang L.J. and He H.M. China Medical Science Press , Pages 1-345. Print ISBN: 978-7-5214-0668-9.
1. 2019, State Scientific & Technological Progress Award, Second Prize, China.
2. 2016, State Scientific & Technological Progress Award, Second Prize, China.
3. 2009, Five Continent Women's Science and Technology Award of China Women Medical Doctor Association - Innovation Award of Basic Medical Research, China.
